TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05805371

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood, stool, and urine sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood, stool, and urine sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo radiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphodepletion Therapy
Description: Undergo lymphodepletion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphodepletion Therapy
Description: Undergo lymphodepletion
Study: NCT06503302

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasound Doppler function detection
Description: Doppler function detection is an ultrasound technique that measures and visualizes blood flow within an object, such as vessels and soft tissue. It can be used to check for the inflammation status of calcifications by detecting blood flow around the calcified areas before performing an ultrasound-guided injection.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound Doppler function detection
Description: Doppler function detection is an ultrasound technique that measures and visualizes blood flow within an object, such as vessels and soft tissue. It can be used to check for the inflammation status of calcifications by detecting blood flow around the calcified areas before performing an ultrasound-guided injection.
Study: NCT03693287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standardized-parenteral nutrition (S-PN)
Description: NUMETA G13%E 300 mL is a triple-chamber (lipid emulsion, amino acids solution with electrolytes, and glucose solution), ready-to-use parenteral nutrition product available to treat preterm infants (less than 37 weeks gestational age).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Personalized-parenteral nutrition (P-PN)
Description: Intravenous glucose will be dextrose 50%, amino acids (AA) will be Primene® and lipids (FAT) will be Clinoleic®.~Parenteral nutrition bags will be prepared by the hospital pharmacy according to the prescription of the attending neonatologist.
Study: NCT06085638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamibarotene
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO~TAMIBAROTENE Azacitidine Azacitidine, 5-azacytidine, 5-aza, Vidaza™, 5-AZC, AZA-CR, Ladakamycin, NSC-102816, Azacytidine Venetoclax ABT-199, GDC-0199, Venetoclax
Study: NCT06649721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bedaquiline
Description: 400 milligrams (mg) daily for 2 weeks(w), then 200mg three times a week for 22 weeks (w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: delamanid
Description: * for participants weighing up to 33.9 kilograms (kg): 50mg two times a day for 24w~* for participants weighing 34kg or above: 100mg two times a day for 8w, then 200mg daily for 16w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linezolid
Description: * for participants weighing up to 33.9kg: 450mg daily;~* for participants weighing 34kg or above: 600mg daily; for 24w if a negative culture is obtained from sputum collected at 16w, or else for 36w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Only for participants with confirmed fluoroquinolone-susceptible TB or unknown fluoroquinolone susceptibility:~* for participants weighing up to 33.9kg: 500mg daily~* for participants weighing 34kg to 49.9kg: 750 daily~* for participants weighing 50kg or above: 1000mg daily for 24w if a negative culture is obtained from sputum collected at 16w, or else for 36w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: Only for participants with confirmed fluoroquinolone-resistant TB or unknown fluoroquinolone susceptibility:~100mg daily, for 24w if a negative culture is obtained from sputum collected at 16w, or else for 36w
Study: NCT06650098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: artificial intelligence-supported mobile application
Description: It is aimed that an artificial intelligence-based mobile application that includes information, nutrition, exercise programs, complications and medication tracking, personalized suggestions, alarms and reminders, which will enable diabetic individuals to follow their glucose targets, support patients in their diabetes education, awareness and disease management to continue more actively. In addition, it is aimed that patients can easily access information, prevent acute and chronic complications, present physical activity and nutrition suggestions in accordance with the person\&#39;s lifestyle, follow up on medications with alarms and reminders, prevent the negative results of complications in advance, and improve individuals\&#39; diabetes-specific knowledge levels, compliance with treatment, self-management and care with information and guidance about foot care to reduce the risk of diabetic feet, which is particularly risky for diabetic patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WEB based application
Description: The content plan for the web-based mobile application group will be prepared with technical support as specified. Patients will be able to log in to the mobile application with a username and password that will be defined specifically for them. Patients will be informed about how the website is used during the first meeting. They will be able to access all the information they need about diabetes with the web-based mobile application. Statistical data such as the frequency of individuals visiting the site, which sections they use more often and how much time they spend will be calculated.
Study: NCT06652737

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ-LARC2 Vaccine
Description: The PfSPZ comprising PfSPZ-LARC2 Vaccine contain a double genetic deletion, of the Mei2 and LINUP genes, and undergo developmental arrest in the late liver stages without releasing merozoites into the blood stream (no blood stage parasites are produced)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ-LARC2 Vaccine
Description: The PfSPZ comprising PfSPZ-LARC2 Vaccine contain a double genetic deletion, of the Mei2 and LINUP genes, and undergo developmental arrest in the late liver stages without releasing merozoites into the blood stream (no blood stage parasites are produced)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ-LARC2 Vaccine
Description: The PfSPZ comprising PfSPZ-LARC2 Vaccine contain a double genetic deletion, of the Mei2 and LINUP genes, and undergo developmental arrest in the late liver stages without releasing merozoites into the blood stream (no blood stage parasites are produced)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ-LARC2 Vaccine
Description: The PfSPZ comprising PfSPZ-LARC2 Vaccine contain a double genetic deletion, of the Mei2 and LINUP genes, and undergo developmental arrest in the late liver stages without releasing merozoites into the blood stream (no blood stage parasites are produced)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ-LARC2 Vaccine
Description: The PfSPZ comprising PfSPZ-LARC2 Vaccine contain a double genetic deletion, of the Mei2 and LINUP genes, and undergo developmental arrest in the late liver stages without releasing merozoites into the blood stream (no blood stage parasites are produced)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (Placebo)
Description: Normal Saline Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (Placebo)
Description: Normal Saline Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (Placebo)
Description: Normal Saline Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (Placebo)
Description: Normal Saline Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (Placebo)
Description: Normal Saline Placebo
Study: NCT06655870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-0184
Description: SC injection
Study: NCT05714306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-DC1
Description: PEP-DC1 vaccine comprises autologous dendritic cells pulsed with personalized peptides detected or predicted a priori (using our current integrated antigen identification methodologies).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OC-DC
Description: OC-DC vaccine is an autologous dendritic cell vaccine loaded with autologous oxidized tumor lysate.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-DC2
Description: PEP-DC2 comprises autologous dendritic cells pulsed with the peptides detected or predicted after vaccination with OC-DC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose cyclophosphamide
Description: Cyclophosphamide administered on D1 of each cycle, the day prior to each vaccination (Vx) at a dose of 200 mg/m2 intravenously (i.v.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose cyclophosphamide
Description: Cyclophosphamide administered on D1 of each cycle, the day prior to each vaccination (Vx) at a dose of 200 mg/m2 intravenously (i.v.)
Study: NCT03639753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Teen Intervention
Description: Parent health coaching and resources + teen on-road driver experience + safe driving eLearning Modules

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Practice
Description: Standard care for teens who get licensed in the state of PA
Study: NCT05614089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Formulation: Available as a clear liquid in a glass cartridge (1 cartridge =3ml=300 units).~Route: Reusable pen~Amount of each dose: varies depending on baseline basal insulin needs~Dose escalation scheme: Participants randomly assigned to glargine will start with a dose that is generally equal to 80% of their total basal human insulin dose prior to the switch (per ISPAD guidelines and the switching guide developed by Life for a Child with the guidance of Dr. Ragnar Hanas and two other ISPAD members familiar with less-resourced settings).~Frequency of dose: once per day (usually administered before bedtime)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH or premixed 70/30 (human insulin)
Description: Drug: NPH or Premixed 70/30 Formulation: Available as a liquid in a glass vial or glass cartridge (10ml=1000IU).~Route: Bangladesh = syringes or reusable pens; Tanzania = disposable pens~Subcutaneous injection using insulin syringe and needle Amount of each dose: varies depending on baseline basal insulin needs (per usual care or treating clinician) Frequency of dose: once or twice per day (per usual care or treating clinician)~Duration of therapy: 12 months~Participants in both groups will receive the same frequency of blood glucose testing and same intensity of education and counseling (e.g. titration advice according to fasting glucose targets and strategies to avoid hypoglycemia). Participants in both groups will have equal access to test strips (sufficient to test up to 5 times per day during the active titration phase and after 3 times/day).
Study: NCT06646692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Self Compassion
Description: (MSC) is a mind-body integrative health intervention that utilizes meditations, other contemplative practices, home practices, and experiential exercises (including group discussions) to increase SC. MSC can be done in groups of 10-25. To increase feasibility of MSC for use in residential drug treatment facilities, we will aim to adapt MSC to 7 sessions (6 weekly sessions in alignment with the MSC short course plus the half day retreat included in the full course to facilitate skill consolidation). Sessions will be conducted in a group-based format: prior research found group-based formats equivalent to individual-level interventions for PTSD/SUD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Description: Selecting appropriate attention control groups for behavioral intervention research, particularly for mindfulness-based interventions, can be problematic. Comparator groups often also improve as they tend to target related mechanisms (e.g., social support, health behaviors, improved attention). After weighing the pros and cons, a treatment as usual (TAU) approach was selected, whereby the MSC will be compared to TAU. However, to control for the confound of weekly compensation, TAU participants will meet with study staff seven times over the 6-week period and fill out short psychosocial surveys on non-distressing topics (e.g., personality tests, attitudes surveys) in exchange for compensation commensurate with the MSC group. We believe this will also help with retention of the TAU group over time and strike an appropriate balance between controlling for the effects of study participation while minimizing confounds that often occur with active control groups in behavioral trials.
Study: NCT06274411

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standby cannulated ECMO
Description: Femoral cannulas are inserted and connected to the primed circuit. Clamps are kept on circuit, and ECMO is on standby during PCI. ECMO is initiated if needed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic ECMO
Description: Prophylactic ECMO procedures are performed in the catheterization laboratory before PCI.
Study: NCT04919616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TILs（Tumor Infiltrating Lymphocytes）
Description: 10e9, 10e10, 10e11 dose range of TILs, 3+3 dose escalation
Study: NCT05598398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V.A.C.Ulta™ Negative Pressure Wound Therapy System
Description: The V.A.C.Ulta™ Negative Pressure Wound Therapy System is a 510(k) - cleared, Class II device (K100657) with the following indication for use: the V.A.C.Ulta™ Negative Pressure Wound Therapy System is an integrated wound management system that provides Negative Pressure Wound Therapy with an instillation option.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (Wet-to-dry dressings)
Description: Wet-to-dry dressings
Study: NCT06359275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1
Description: Toripalimab，240 mg/time，D1， Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel, 125mg/m2，IV，D1，8, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine，1000mg/m2，IV，D1，8，Q3W

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PULSAR
Description: 5-10 Gy per session, a total of 5 times.
Study: NCT04844411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-67835989
Description: JNJ-67835989 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-67835989
Description: JNJ-67835989 will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered orally.
Study: NCT06476782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Relearning Program(MRP) and aerobic exercise
Description: Participants of this group received training for a total of 8 weeks in the form of 3 sessions per week each session of 40 minutes, with a total of 24 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Relearning Program(MRP)
Description: the week 8 session was held in which patients were involved in 60-minute activities that involved practicing functional tasks without explicitly giving any type of relationship between those learned skills and the remedial tasks.
Study: NCT05675995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External Qigong
Description: 6 sessions of external qigong delivered in a group-based format once a week.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: External Qigong
Description: 6 sessions of external qigong delivered in a group-based format once a week.
Study: NCT06385301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-minute walk distance (6MWD) test on ambient air
Description: 6-minute walk distance (6MWD) test will be performed on ambient air according to clinical standards

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6-minute walk distance test with supplemental oxygen (approximately 3l/min, nasal)
Description: 6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (approximately 3l/min, nasal)
Study: NCT06655194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (Aspirin, BAYE004465, UI1610477)
Description: Chewable tablet, 81mg, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (Aspirin, BAYE004465, UI1610477)
Description: Chewable tablet, 81mg, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (BAYE004465, UI1615160)
Description: Chewable tablet, 81 mg, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (BAYE004465, UI1615160)
Description: Chewable tablet, 81 mg, oral
Study: NCT06414733

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 720
Description: Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified in ISA 720 vehicle. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with a Montanide ISA 720, and will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 720
Description: Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified in ISA 720 vehicle. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with a Montanide ISA 720, and will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.
Study: NCT05307094

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Improving Parents as Communication Teachers
Description: A parent-mediated naturalistic developmental behavioral intervention delivered 2-times per week with a primary caregiver and the child.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving Parents as Communication Teachers
Description: A parent-mediated naturalistic developmental behavioral intervention delivered 2-times per week with a primary caregiver and the child.
Study: NCT06593587

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF Vaccine
Description: RSV Vaccine 120 mcg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06656572

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic: Genomic sequencing and molecular diagnostic results, if any.
Description: Genomic sequencing results may be used for diagnosis and treatment of participants.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)
Description: Whole Proteome programmable phage display immunoprecipitation sequencing will be used to diagnose known and novel autoantibodies.
Study: NCT06662292

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile STRIDES app (psychoeducation features)
Description: Twelve theory-based physical activity behavior change lessons/modules during the course of the 3-month intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile STRIDES app (psychoeducation features)
Description: Twelve theory-based physical activity behavior change lessons/modules during the course of the 3-month intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile STRIDES app (self-regulation features)
Description: Personalized physical activity goals focused on moderate-to-vigorous intensity aerobic physical activity and steps. Physical activity (tracked with a Fitbit wearable smartwatch and synced with the Mobile STRIDES app) tracking component, displaying team and individual progress. Weekly individualized feedback messages crafted by a trained professional for the first month of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile STRIDES app (self-regulation features)
Description: Personalized physical activity goals focused on moderate-to-vigorous intensity aerobic physical activity and steps. Physical activity (tracked with a Fitbit wearable smartwatch and synced with the Mobile STRIDES app) tracking component, displaying team and individual progress. Weekly individualized feedback messages crafted by a trained professional for the first month of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile STRIDES app (social support training features)
Description: For the experimental group, the Mobile STRIDES app also includes five social support training lessons/modules (during the course of the 3-month intervention) focused on providing guidance related to effective communication when exchanging social support for physical activity within a team. In addition, six team feedback messages will be delivered to respective teams throughout the course of the 3-month intervention to reinforce content taught via the training lessons/modules. A weekly poll will also be administered that complements the social support training lessons, with cumulative results displayed.